AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Barlow Wealth Partners Inc.

Barlow Wealth Partners Inc. raised its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 2.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 240,887 shares of the company’s stock after buying an additional 4,799 shares during the period. AstraZeneca comprises about 2.4% of Barlow Wealth Partners Inc.’s holdings, making the stock its 12th largest holding. Barlow Wealth Partners Inc.’s holdings in AstraZeneca were worth $18,517,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its stake in AstraZeneca by 17.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock valued at $4,151,177,000 after buying an additional 9,002,450 shares in the last quarter. Swedbank AB acquired a new position in AstraZeneca in the 1st quarter valued at about $186,127,000. Manning & Napier Advisors LLC acquired a new position in AstraZeneca in the 2nd quarter valued at about $188,476,000. Hsbc Holdings PLC boosted its holdings in AstraZeneca by 750.3% in the 2nd quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company’s stock valued at $100,523,000 after purchasing an additional 1,132,362 shares in the last quarter. Finally, Farallon Capital Management LLC boosted its holdings in AstraZeneca by 65.1% in the 2nd quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company’s stock valued at $187,934,000 after purchasing an additional 950,000 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Barclays raised AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. TD Cowen boosted their price target on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. Citigroup upgraded AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Finally, Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $89.75.

AstraZeneca Stock Down 0.2 %

Shares of AZN stock traded down $0.14 during trading hours on Wednesday, hitting $76.73. 388,785 shares of the company were exchanged, compared to its average volume of 5,148,180. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The business’s 50-day simple moving average is $81.57 and its two-hundred day simple moving average is $77.68. The stock has a market capitalization of $237.91 billion, a price-to-earnings ratio of 37.68, a P/E/G ratio of 1.43 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.01. The firm had revenue of $12.45 billion for the quarter, compared to analyst estimates of $12.62 billion. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. AstraZeneca’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.08 earnings per share. Sell-side analysts predict that AstraZeneca PLC will post 4.08 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Monday, September 9th. Shareholders of record on Friday, August 9th were paid a $0.49 dividend. The ex-dividend date of this dividend was Friday, August 9th. This represents a dividend yield of 1.8%. AstraZeneca’s payout ratio is currently 48.04%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.